

Stefano Bignotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198250/publications.pdf>

Version: 2024-02-01

31
papers

1,906
citations

304368

22
h-index

433756

31
g-index

31
all docs

31
docs citations

31
times ranked

3055
citing authors

#	ARTICLE	IF	CITATIONS
1	The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. <i>Schizophrenia Research</i> , 1998, 32, 9-15.	1.1	297
2	Blood microRNA changes in depressed patients during antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 602-611.	0.3	197
3	Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. <i>Schizophrenia Research</i> , 2002, 54, 281-291.	1.1	155
4	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. <i>Journal of Affective Disorders</i> , 2006, 91, 83-86.	2.0	137
5	Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. <i>European Neuropsychopharmacology</i> , 2000, 10, 119-124.	0.3	127
6	Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. <i>Schizophrenia Research</i> , 2003, 60, 47-55.	1.1	100
7	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 480-484.	0.7	81
8	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. <i>Neuroscience Letters</i> , 2008, 437, 130-134.	1.0	79
9	Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. <i>Clinical Neurophysiology</i> , 2005, 116, 1062-1071.	0.7	78
10	Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 416-418.	4.1	69
11	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. <i>PLoS ONE</i> , 2015, 10, e0116686.	1.1	65
12	Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. <i>Biological Psychiatry</i> , 2003, 53, 617-619.	0.7	57
13	Structural brain features of borderline personality and bipolar disorders. <i>Psychiatry Research - Neuroimaging</i> , 2013, 213, 83-91.	0.9	43
14	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. <i>Depression and Anxiety</i> , 2013, 30, 1170-1176.	2.0	42
15	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. <i>Psychiatry Research</i> , 2001, 104, 1-9.	1.7	40
16	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 132B, 1-4.	1.1	39
17	Dorsolateral prefrontal transcranial magnetic stimulation in patients with major depression locally affects alpha power of REM sleep. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 433.	1.0	38
18	Abnormal Levels of cAMP-dependent Protein Kinase Regulatory Subunits in Platelets from Schizophrenic Patients. <i>Neuropsychopharmacology</i> , 2000, 23, 216-219.	2.8	36

#	ARTICLE	IF	CITATIONS
19	Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case-control study. <i>American Journal of Medical Genetics Part A</i> , 2004, 128B, 27-29.	2.4	33
20	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. <i>Psychiatry Research - Neuroimaging</i> , 2019, 283, 118-124.	0.9	33
21	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. <i>Neuropsychobiology</i> , 2002, 46, 17-21.	0.9	27
22	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e687-e687.	2.4	26
23	3â€² UTR (AGG) _n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. <i>Neuroscience Letters</i> , 2004, 357, 235-237.	1.0	24
24	Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 63-75.	2.2	20
25	Abnormalities in Cortical Gray Matter Density in Borderline Personality Disorder. <i>European Psychiatry</i> , 2015, 30, 221-227.	0.1	19
26	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 183, 179-186.	2.0	17
27	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. <i>BMC Psychiatry</i> , 2012, 12, 145.	1.1	16
28	Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. <i>Psychiatric Genetics</i> , 2010, 20, 44-45.	0.6	4
29	Neurobiological and clinical effect of metacognitive interpersonal therapy vs structured clinical model: study protocol for a randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 195.	1.1	4
30	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq0 0 0 rgB0,0 Overlock 10 Tf 50		
31	Depressive symptomatology during clozapine treatment: two case reports. <i>European Neuropsychopharmacology</i> , 1998, 8, 239-240.	0.3	1